Drug treatment for spinal muscular atrophy type I

Cochrane Database of Systematic Reviews

Volumn 2019, Issue 12, 2019, Pages

  Wadman, Renske I ^a   van der Pol, W Ludo ^a   Bosboom, Wendy MJ ^b   Asselman, Fay Lynn ^a   van den Berg, Leonard H ^a   Iannaccone, Susan T ^c   Vrancken, Alexander FJE ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRANAPLAM; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; NUSINERSEN; PHENYLBUTYRATE; PLACEBO; RECOMBINANT CILIARY NEUROTROPHIC FACTOR; RG 7800; RILUZOLE; RISDIPLAM; RO 6885247; SURVIVAL MOTOR NEURON PROTEIN 1; UNCLASSIFIED DRUG; VALPROIC ACID; NEUROPROTECTIVE AGENT; OLIGONUCLEOTIDE;

ADVERSE DRUG REACTION; AGE; ARTIFICIAL VENTILATION; CHILD DEVELOPMENT; CLINICAL ASSESSMENT; DATA ANALYSIS; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; DRUG THERAPY; EVIDENCE BASED MEDICINE; FUNDING; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; HEAD; HUMAN; INTERIM ANALYSIS; META ANALYSIS; MORTALITY; MOTOR DEVELOPMENT; MOTOR DYSFUNCTION; OVERALL SURVIVAL; PRIORITY JOURNAL; QUASI EXPERIMENTAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SITTING; SMN1 GENE; STANDING; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; WERDNIG HOFFMANN DISEASE; HEREDITARY SPINAL MUSCULAR ATROPHY; INFANT; PRESCHOOL CHILD; DISEASE COURSE;

CHILD, PRESCHOOL; HUMANS; INFANT; NEUROPROTECTIVE AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RILUZOLE; SPINAL MUSCULAR ATROPHIES OF CHILDHOOD; DISEASE PROGRESSION; OLIGONUCLEOTIDES;

EID: 84864050619     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006281.pub5     Document Type: Review

References (216)

1. Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. New England Journal of Medicine 2017;377(18):1723-32. x-wiley/crsRef/12315315
2. NCT02193074. A study to assess the efficacy and safety of IONIS-SMN rx in infants with spinal muscular atrophy [A phase 3, randomized, double-blind, sham-procedure controlled study to assess the clinical efficacy and safety of IONIS 396443 administered intrathecally in patients with infantile-onset spinal muscular atrophy]. clinicaltrials.gov/show/NCT02193074 (first received 14 July 2014). [IONIS 396443-CS3B; NCT02193074]x-wiley/crsRef/12315316
3. Russman BS, Iannaccone ST, Samaha FJ. A phase 1 trial of riluzole in spinal muscular atrophy. Archives of Neurology 2003;60(11):1601-3. [PUBMED: 14623733]x-wiley/crsRef/3071649
4. Brichta L, Holker I, Haug K, Klockgether T, Wirth B. In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Annals of Neurology 2006;59(6):970-5. x-wiley/crsRef/3071651
5. Krosschell KJ, Kissel JT, Townsend EL, Simeone SD, Zhang RZ, Reyna SP, et al. Project Cure SMA Investigator's Network. Clinical trial of L-Carnitine and valproic acid in spinal muscular atrophy type I. Muscle & Nerve 2018;57(2):193-9. [CTG: NCT00661453; 25409 IND 79276]x-wiley/crsRef/12315318
6. Chang JG, Tsai FJ, Wang WY, Jong YJ. Treatment of spinal muscular atrophy by hydroxyurea. American Journal of Human Genetics 2002;71(Suppl 4):2402. x-wiley/crsRef/3071653
7. Conceicao E, Silva T, Umbertine R, Maria Joaquina D. Analysis of motor skill acquisition among children with type I spinal muscular atrophy submitted to medication with valproic acid. Amyotrophic Lateral Sclerosis 2010;11(Suppl 1):63-71. x-wiley/crsRef/12315320
8. Finkel R, Chiriboga C, Vajsar J, Day J, Montes J, De Vivo D, et al. Interim results of a phase 2 clinical study of nusinersen (ISIS-SMNRx) in patients with infantile-onset spinal muscular atrophy. Annals of Neurology 2016;80(Suppl 20):S371-2. x-wiley/crsRef/12315322
9. Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 2016;388(10063):3017-26. x-wiley/crsRef/12315323
10. NCT01839656. A study to assess the safety and pharmacokinetics of ionis SMNRX in infants with spinal muscular atrophy [A study to assess the efficacy, safety, tolerability, and pharmacokinetics of multiple doses of ISIS 396443 delivered intrathecally to patients with infantile-onset spinal muscular atrophy]. www.clinicaltrials.gov/show/NCT01839656 (first received 22 April 2013). [CTG: NCT01839656; IONIS SMNRx 396443 - CS3A]x-wiley/crsRef/12315324
11. NCT02913482. A study to Investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type1 spinal muscular atrophy (Firefish) [A two part seamless, open-label, multicenter study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type 1 spinal muscular atrophy]. clinicaltrials.gov/show/NCT02913482 (first received 21 September 2016). [ClinicalTrials.go: NCT02913482]x-wiley/crsRef/12315326
12. Franz DN, Tudor CA, Samaha FJ. A phase I trial of recombinant human ciliary neurotrophic factor in spinal muscular atrophy. Annals of Neurology 1995; Vol. 38, issue 3:546. x-wiley/crsRef/3071655
13. JPRN-JapicCTI-163450. Phase 3 study of K-828-SP [Phase 3 study of K-828-SP (Long-term study of sodium valproate in child patients with spinal muscular atrophy)]. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-JapicCTI-163450 (first received November 2016). x-wiley/crsRef/12315328
14. Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac L, Kissel JT, et al. Gene therapy for spinal muscular atrophy type 1 shows potential to improve survival and motor functional outcomes. Molecular Therapy 2016;24(Suppl 1):S190. [EMBASE: 72276590; WOS:000375264200475]x-wiley/crsRef/12315330
15. Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Gene-Replacement Therapy for Spinal Muscular Atrophy. New England Journal of Medicine 2017;377(18):1713-22. x-wiley/crsRef/12315331
16. NCT02122952. Gene transfer clinical trial for spinal muscular atrophy type 1 [Phase I gene transfer clinical trial for spinal muscular atrophy type 1 delivering AVXS-101]. www.clinicaltrial.gov/show/NCT0122952 (first received 23 April 2014). [CTG: NCT02122952; AVXS-101-CL-101]x-wiley/crsRef/12315332
17. Sproule D, Al-Zaidy S, Shell R, Arnold D, Rodino-Klapac L, Kissel J, et al. Interim safety, efficacy and achievement of developmental milestones in this phase 1, first-in-human study of the systemic delivery of AVXS-101, an AAV9-mediated gene therapy for children with spinal muscular atrophy (SMA) type 1. Annals of Neurology 2016;80(Suppl 20):S368. x-wiley/crsRef/12315333
18. NCT02268552. An open label study of LMI070 in type 1 spinal muscular atrophy (SMA) [An open label multi-part first-in-human study of oral LMI070 in infants with type 1 spinal muscular atrophy]. www.clinicaltrials.gov/show/NCT02268552 (first received 1 October 2014). [CTG: NCT02268552; Sponsor's Protocol Code Number: CLMI070X2201]x-wiley/crsRef/3071665
19. NCT02855112. Allogeneic adipose derived stem cells for Werdnig Hoffman patients [The effectiveness of allogeneic adipose derived mesenchymal stem cells (ADMSCs) in the phenotypic changes of Werdnig Hoffman patients]. clinicaltrials.gov/show/NCT02855112 (first received 22 July 2016. [CTG: NCT02855112]x-wiley/crsRef/12315335
20. NCT02865109. To provide access to nusinersen to eligible patients with Infantile-onset Spinal Muscular Atrophy (SMA) (consistent with Type 1) to address a high-unmet medical need. clinicaltrials.gov/show/NCT02865109 (first received10 August 2016). x-wiley/crsRef/12315337
21. NCT00439218. Clinical trial of sodium phenylbutyrate in children with spinal muscular atrophy type I [Phase I/IIa clinical trial of sodium phenylbutyrate in pediatric subjects with type I spinal muscular atrophy]. clinicaltrials.gov/show/NCT00439218 (first received 22 February 2007). [CTG: NCT00439218; HHSN265200423611C; N01NS42361_NPTUNE02]x-wiley/crsRef/12315339
22. Prufer de Queiroz Campos Araujo A. Long-term open salbutamol trial in spinal muscular atrophy. Journal of Neurology 2010;257(Suppl 1):S101. x-wiley/crsRef/3071667
23. NCT02594124. An open-label study (SHINE) for patients with spinal muscular atrophy (sma) who participated in studies with IONIS-SMNRX [An open-label extension study for patients with spinal muscular atrophy who previously participated in investigational studies of ISIS 396443]. clinicaltrials.gov/show/NCT02594124 (first received 30 October 2015). [CTG: NCT02594124; EudraCT: EUCTR2015-001870-16-DE; Sponsor's Protocol Code Number: ISIS 396443-CS11]x-wiley/crsRef/12315341
24. SMART01. Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy. dbcentre3.jmacct.med.or.jp/JMACTR/App/JMACTRS06/JMACTRS06.aspx?seqno=4602 (first received July 2014). [JPRN-SMA-IIA00190]x-wiley/crsRef/12315343
25. Swoboda KJ, Scott CB, Reyna SP, Prior TW, LaSalle B, Sorenson SL, et al. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One 2009;4(5):e5268. [PUBMED: 19440247]x-wiley/crsRef/3071669
26. Villanova M, Bach JR. Allogeneic mesenchymal stem cell therapy outcomes for three patients with spinal muscular atrophy type 1. American Journal of Physical Medicine & Rehabilitation 2015;94(5):410-5. x-wiley/crsRef/12315345
27. MOONFISH - NCT02240355. A study of RO6885247 in adult and pediatric patients with spinal muscular atrophy (MOONFISH) [A multicenter, randomized, double blind, placebo controlled, multiple dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6885247 following 12 weeks of treatment in adult and pediatric patients with spinal muscular atrophy (MOONFISH)]. clinicaltrials.gov/show/NCT02240355 (first received 11 September 2014). [CTG: NCT02240355; 2014-002246-41; BP29420]x-wiley/crsRef/12315347
28. NCT00568698. A pilot therapeutic trial using hydroxyurea in type I spinal muscular atrophy patients. clinicaltrials.gov/show/NCT00568698 (first received 4 December 2007). [78811; NCT00083746; NCT00568698; SU-11012007-783]x-wiley/crsRef/12315349
29. NCT02462759. A study to assess the safety and tolerability of ISIS 396443 (ISIS SMNRx) in participants with spinal muscular atrophy (SMA). (EMBRACE) [A phase 2, randomized, double-blind, sham-procedure controlled study to assess the safety and tolerability and explore the efficacy of ISIS 396443 (BIIB058) administered intrathecally in subjects with spinal muscular atrophy who are not eligible to participate in the clinical studies ISIS 396443-CS3B or ISIS 396443-CS4]. clinicaltrials.gov/show/NCT02462759 (first received 14 May 2015). [CTG: NCT02462759; EudraCT: EUCTR2014-003657-33-DE; 232SM202]x-wiley/crsRef/12315351
30. SMART02. Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy: confirmatory trial (SMART02). dbcentre3.jmacct.med.or.jp/JMACTR/App/JMACTRS06/JMACTRS06.aspx?seqno=5544 (first received January 2016). [27-3594; JPRN-JMA-IIA00231]x-wiley/crsRef/12315353
31. Abbara C, Estournet B, Lacomblez L, Lelièvre B, Ouslimani A, Lehmann B, et al. Riluzole pharmacokinetics in young patients with spinal muscular atrophy. British Journal of Clinical Pharmacology 2011;71(3):403-10.
32. Abera MB, Xiao J, Nofziger J, Titus S, Southall N, Zheng W, et al. ML372 blocks SMN ubiquitination and improves spinal muscular atrophy pathology in mice. JCI Insight 2017;1(19):e88427.
33. ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 1996;46(5):1244-9.
34. Also-Rallo E, Alias L, Martinez-Hernandez R, Caselles L, Barcelo MJ, Baiget M, et al. Treatment of spinal muscular atrophy cells with drugs that upregulate SMN expression reveals inter- and intra-patient variability. European Journal of Human Genetics 2011;19:1059-65.
35. Anderton RS, Mastaglia FL. Advances and challenges in developing a therapy for spinal muscular atrophy. Expert Review of Neurotherapeutics 2015;15(8):895-908.
36. Ando S, Funato M, Ohuchi K, Kameyama T, Inagaki S, Seki J, et al. Edaravone is a candidate agent for spinal muscular atrophy: In vitro analysis using a human induced pluripotent stem cells-derived disease model. European Journal of Pharmacology 2017;814:161-8.
37. Andreassi C, Angelozzi C, Tiziano FD, Vitali T, De Vincenzi E, Boninsegna A, et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. European Journal of Human Genetics 2004;12(1):59-65.
38. Angelini C, Micaglio GF, Trevisan C. Guanidine hydrochloride in infantile and juvenile spinal muscular atrophy. A double blind controlled study. Acta Neurologica 1980;2(6):460-5.
39. Arkblad E, Tulinius M, Kroksmark AK, Henricsson M, Darin N. A population-based study of genotypic and phenotypic variability in children with spinal muscular atrophy. Acta Paediatrica 2009;98(5):865-72.
40. Arnold WD, Burghes AHM. Spinal Muscular Atrophy: the development and implementation of potential treatments running head. Annals of Neurology 2013;74(3):348-62.
41. ASIRI - NCT00774423. Study to evaluate the efficacy of riluzole in children and young adults with spinal muscular atrophy (SMA) (ASIRI) [Multicentric, randomized, double-blind study versus placebo, with two parallel groups treated to evaluate the efficacy and the tolerance of riluzole in children and young adults (6 to 20 years of age) with SMA. (Type II and Type III)]. www.clinicaltrials.gov/show/NCT00774423 (first received 16 October 2008). [NCT00774423; P040904]
42. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490.
43. Avila AM, Burnett BG, Taye AA, Gabanella F, Knight MA, Hartenstein P, et al. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. Journal of Clinical Investigation 2007;117(3):659-71.
44. Azzouz M, Le T, Ralph GS, Walmsley L, Monani UR, Lee DC, et al. Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. Journal of Clinical Investigation 2004;114(12):1726-31.
45. Benkhelifa-Ziyyat S, Besse A, Roda M, Duque S, Astord S, Carcenac R, et al. Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice. Molecular Therapy 2013;21(2):282-90.
46. Bertini E, Dessaud E, Mercuri E, Muntoni F, Kirschner J, Reid C, et al. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurology 2017;S1474-4422(17):30085-6. [NCT01302600; TRO19622 CLEQ 1275-1]
47. Bladen CL, Thompson R, Jackson JM, Garland C, Wegel C, Ambrosini A, et al. Mapping the differences in care for 5,000 spinal muscular atrophy patients, a survey of 24 national registries in North America, Australasia and Europe. Jounal of Neurology 2014;261(1):152-63.
48. Bogdanik LP, Osborne MA, Davis C, Martin WP, Austin A, Rigo F, et al. Systemic, postsymptomatic antisense oligonucleotide rescues motor unit maturation delay in a new mouse model for type II/III spinal muscular atrophy. Proceedings of the National Academy of Sciences of United States of America 2015;112(43):E5863-72.
49. Bongioanni P, Reali C, Sogos V. Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD004302.pub2]
50. Bowerman M, Beauvais A, Anderson CL, Kothary R. Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model. Human Molecular Genetics 2010;19(8):1468-78.
51. Bowerman M, Murray LM, Boyer JG, Anderson CL, Kothary R. Fasudil improves survival and promotes skeletal muscle development in a mouse model of spinal muscular atrophy. BMC Medicine 2012;7(10):24.
52. Brahe C, Vitali T, Tiziano FD, Angelozzi C, Pinto AM, Borgo F, et al. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. European Journal of Human Genetics 2005;13(2):256-9.
53. Braun S, Croizat B, Lagrange MC, Warter JM, Poindron P. Constitutive muscular abnormalities in culture in spinal muscular atrophy. Lancet 1995;345(8951):694-5. [PUBMED: 7741893]
54. Brichta L, Hofmann Y, Hahnen E, Siebzehnrubl FA, Raschke H, Blumcke I, et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Human Molecular Genetics 2003;12(19):2481-9.
55. Bryson HM, Fulton B, Benfield P. Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Drugs 1996;52(4):549-63.
56. Brzustowicz LM, Lehner T, Castilla LH, Penchaszadeh GK, Wilhelmsen KC, Daniels R, et al. Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3. Nature 1990;344(6266):540-1.
57. Burghes AH, Beattie CE. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?. Nature Reviews Neuroscience 2009;10(8):597-609.
58. Butchbach ME, Singh J, Thorsteinsdottir M, Saieva L, Slominski E, Thurmond J, et al. Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Human Molecular Genetics 2010;19(3):454-67.
59. Butchbach ME, Lumpkin CJ, Harris AW, Saieva L, Edwards JD, Workman E, et al. Protective effects of butyrate-based compounds on a mouse model for spinal muscular atrophy. Experimental Neurology 2016;279:13-26.
60. Chen YC, Chang JG, Liu TY, Jong YJ, Cheng WL, Yuo CY. Securinine enhances SMN2 exon 7 inclusion in spinal muscular atrophy cells. Biomedicine & Pharmacotherapy 2017;88:708-14.
61. Cherry JJ, DiDonato CJ, Androphy EJ, Calo A, Potter K, Custer SK, et al. In vitro and in vivo effects of 2,4 diaminoquinazoline inhibitors of the decapping scavenger enzyme DcpS: Context-specific modulation of SMN transcript levels. PLoS One 2017;12(9):eCollection 2017.
62. Cifuentes-Diaz C, Frugier T, Melki J. Spinal muscular atrophy. Seminars in Pediatric Neurology 2002;9(2):145-50. [PUBMED: 12138998]
63. Cobben JM, van der Steege, Grootscholten P, de Visser M, Scheffer H, Buys CH. Deletions of the survival motor neuron gene in unaffected siblings of patients with spinal muscular atrophy. American Journal of Human Genetics 1995;57(4):805-8.
64. Cobben JM, de Visser M, Scheffer H. From gene to disease; 'survival' motor neuron protein and hereditary proximal spinal muscle atrophy. Nederlands Tijdschrift voor Geneeskunde 2001;145(52):2525-7.
65. Cobben JM, Lemmink HH, Snoeck I, Barth PA, van der Lee JH, de Visser M. Survival in SMA type I: a prospective analysis of 34 consecutive cases. Neuromuscular Disorders 2008;18(7):541-4.
66. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd Edition. Routledge, 1988.
67. d'Ydewalle C, Ramos DM, Pyles NJ, Ng SY, Gorz M, Pilato CM, et al. The antisense transcript SMN-AS1 regulates SMN expression and Is a novel therapeutic target for spinal muscular atrophy. Neuron 2017;93(1):66-79.
68. Darbar IA, Plaggert PG, Resende MB, Zanotelli E, Reed UC. Evaluation of muscle strength and motor abilities in children with type II and III spinal muscle atrophy treated with valproic acid. BMC Neurology 2011;11:36.
69. Darras BT, Kang PB. Clinical trials in spinal muscular atrophy. Current Opinion in Pediatrics 2007;19(6):675-9.
70. Dominguez E, Marais T, Chatauret N, Benkhelifa-Ziyyat S, Duque S, Ravassard P, et al. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Human Molecular Genetics 2011;20(4):681-93.
71. Donnelly EM, Boulis NM. Update on gene and stem cell therapy approaches for spinal muscular atrophy. Expert Opinion on Biological Therapy 2012;11:1463-71.
72. Dubowitz V. Chaos in the classification of SMA: a possible resolution. Neuromuscular Disorders 1995;5(1):3-5.
73. Duque SI, Arnold WD, Odermatt P, Li X, Porensky PN, Schmelzer L, et al. A large animal model of spinal muscular atrophy and correction of phenotype. Annals of Neurology 2015;77(3):399-414.
74. Edwards JD, Butchbach ME. Effect of the butyrate prodrug pivaloyloxymethyl butyrate (AN9) on a mouse model for spinal muscular atrophy. Journal of Neuromuscular Disorders 201629;3(4):511-5.
75. Feldkotter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. American Journal of Human Genetics 2002;70(2):358-68.
76. Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK, Sproule DM, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology 2014;83(9):810-7.
77. Finkel R, Bertini E, Muntoni F, Mercuri E, ENMC SMA Workshop Study Group. 209th ENMC International Workshop: Outcome Measures and Clinical Trial Readiness in Spinal Muscular Atrophy 7-9 November 2014, Heemskerk, The Netherlands. Neuromuscular Disorders 2015;25(7):593-602.
78. Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromusculular Disordorders 2018;28(3):197-207.
79. Folkers K, Simonsen R. Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. Biochimica et Biophysica Acta 1995;1271(1):281-6.
80. Foust KD, Wang X, McGovern VL, Braun L, Bevan AK, Haidet AM, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nature Biotechnology 2010;28(3):271-4.
81. Garbes L, Riessland M, Hölker I, Heller R, Hauke J, Tränkle C, et al. LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate. Human Molecular Genetics 2009;18(19):3645-58.
82. Gavrilina TO, McGovern VL, Workman E, Crawford TO, Gogliotti RG, DiDonato CJ, et al. Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect. Human Molecular Genetics 2008;17(8):1063-75.
83. Gendron NH, MacKenzie AE. Spinal muscular atrophy: molecular pathophysiology. Current Opinion in Neurology 1999;12(2):137-42.
84. Gilliam TC, Brzustowicz LM, Castilla LH, Lehner T, Penchaszadeh GK, Daniels RJ, et al. Genetic homogeneity between acute and chronic forms of spinal muscular atrophy. Nature 1990;345(6278):823-5.
85. Glascock JJ, Shababi M, Wetz MJ, Krogman MM, Lorson CL. Direct central nervous system delivery provides enhanced protection following vector mediated gene replacement in a severe model of spinal muscular atrophy. Biochemical and Biophysical Research Communications 2012;417:376-81.
86. Glascock JJ, Osman EY, Wetz MJ, Krogman MM, Shababi M, Lorson CL. Decreasing disease severity in symptomatic, SMN(–/–);SMN2(+/+), spinal muscular atrophy mice following scAAV9-SMN delivery. Human Gene Therapy 2012;23(3):330-5.
87. Gogliotti RG, Cardona H, Singh J, Bail S, Emery C, Kuntz N, et al. The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. Human Molecular Genetics 2013;22(20):4048-101.
88. McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed prior to 2 September 2019. Hamilton (ON): McMaster University (developed by Evidence Prime).
89. Chen TH, Chang JG, Yang YH, Mai HH, Liang WC, Wu YC, et al. Randomized, double-blind, placebo-controlled trial of hydroxyurea in spinal muscular atrophy. Neurology 2010;75(24):2190-7.
90. Haddad H, Cifuentes-Diaz C, Miroglio A, Roblot N, Joshi V, Melki J. Riluzole attenuates spinal muscular atrophy disease progression in a mouse model. Muscle & Nerve 2003;28(4):432-7.
91. Hadwen J, MacKenzie D, Shamim F, Mongeon K, Holcik M, MacKenzie A, et al. VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models. Orphanet Journal of Rare Diseases 2014;9:4.
92. Hahnen E, Eyüpoglu IY, Brichta L, Haastert K, Tränkle C, Siebzehnrübl FA, et al. In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. Journal Neurochemistry 2006;98(1):193-202.
93. Hammond SM, Hazell G, Shabanpoor F, Saleh AF, Bowerman M, Sleigh JN, et al. Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proceedings of the National Academy of Sciences in the United States of America 2016;113(39):10962-7.
94. Harada Y, Sutomo R, Sadewa AH, Akutsu T, Takeshima Y, Wada H, et al. Correlation between SMN2 copy number and clinical phenotype of spinal muscular atrophy: three SMN2 copies fail to rescue some patients from the disease severity. Journal of Neurology 2002;249(9):1211-9.
95. Hastings ML, Berniac J, Liu YH, Abato P, Jodelka FM, Barthel L, et al. Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy. Science Translational Medicine 2009;1(5):5ra12.
96. Hauke J, Riessland M, Lunke S, Eyüpoglu IY, Blümcke I, El-Osta A, et al. Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition. Human Molecular Genetics 2009;18(2):304-17.
97. Heier CR, DiDonato CJ. Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo. Human Molecular Genetics 2009;18(7):1310-22.
98. Heier CR, DiDonato CJ. ECG in neonate mice with spinal muscular atrophy allows assessment of drug efficacy. Frontiers in Bioscience (Elite Edition) 2015;1(7):107-15.
99. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration: Available from www.cochrane-handbook.org.
100. Hosseinibarkooie S, Peters M, Torres-Benito L, Rastetter RH, Hupperich K, Hoffmann A, et al. The power of human protective modifiers: PLS3 and CORO1C unravel impaired endocytosis in spinal muscular atrophy and rescue SMA phenotype. American Journal of Human Genetics 2016;99(3):647-65.
101. Hsu YY, Jong YJ, Tsai HH, Tseng YT, An LM, Lo YC. Triptolide increases transcript and protein levels of survival motor neurons in human SMA fibroblasts and improves survival in SMA-like mice. British Journal of Pharmacology 2012;166(3):1114-26.
102. Hua Y, Sahashi K, Hung G, Rigo F, Passini MA, Bennett CF, et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes & Development 2010;24(15):1634-44.
103. Hua Y, Sahashi K, Rigo F, Hung G, Horev G, Bennett CF, et al. Peripheral SMN restoration is essential for long-term rescue of a severe SMA mouse model. Nature 2011;478(7367):123-6.
104. Iannaccone ST, Browne RH, Samaha FJ, Buncher CR. Prospective study of spinal muscular atrophy before age 6 years. DCN/SMA Group. Pediatric Neurology 1993;9(3):187-93.
105. Iannaccone ST. Spinal muscular atrophy. Seminars in Neurology 1998;18(1):19-26.
106. Iannaccone ST, Burghes AH. Spinal muscular atrophies. In: Rahman Pourmand, Yadollah Harati editor(s). Neuromuscular Disorders. Philadelphia: Lippincott Williams and Wilkins, 2001:83-98.
107. Il'ina NA, Antipova RI, Khokhlov AP. Use of lithium carbonate to treat Kugelberg-Welander spinal amyotrophy [Primenenie uglekislogo litiia dlia lecheniia spinal'noi amiotrofii Kugel'berga-Velandera]. Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova 1980;80(11):1657-60.
108. Jablonka S, Rossoll W, Schrank B, Sendtner M. The role of SMN in spinal muscular atrophy. Journal of Neurology 2000;247(Suppl 1):I37-42.
109. Jarecki J, Chen X, Bernardino A, Coovert DD, Whitney M, Burghes A, et al. Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Human Molecular Genetics 2005;14(14):2003-18.
110. Kaczmarek A, Schneider S, Wirth B, Riessland M. Investigational therapies for the treatment of spinal muscular atrophy. Expert Opinion on Investigational Drugs 2015;24(7):967-81.
111. Kariya S, Park GH, Maeno-Hikichi Y, Leykekhman O, Lutz C, Arkovitz MS, et al. Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Human Molecular Genetics 2008;17(16):2552-69. [PUBMED: 18492800]
112. Keil JM, Seo J, Howell MD, Hsu WH, Singh RN, DiDonato CJ. A short antisense oligonucleotide ameliorates symptoms of severe mouse models of spinal muscular atrophy. Molecular Therapy - Nucleic Acids 2014;3:e174.
113. Kernochan LE, Russo ML, Woodling NS, Huynh TN, Avila AM, Fischbeck KH, et al. The role of histone acetylation in SMN gene expression. Human Molecular Genetics 2005;14(9):1171-82.
114. Kim JE, Kim DS, Kwak SE, Choi HC, Song HK, Choi SY, et al. Anti-glutamatergic effect of riluzole: comparison with valproic acid. Neuroscience 2007;147(1):136-45.
115. Kissel JT, Scott CB, Reyna SP, Crawford TO, Simard LR, Krosschell KJ, et al. SMA carni-val trial part II: a prospective, single- armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy. PLoS ONE 2011;6(7):e21296.
116. Kroksmark AK, Beckung E, Tulinius M. Muscle strength and motor function in children and adolescents with spinal muscular atrophy II and III. European Journal of Paediatric Neurology 2001;5(5):191-8.
117. Kwon DY, Motley WW, Fischbeck KH, Burnett BG. Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice. Human Molecular Genetics 2011;20(18):3667-77.
118. Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995;80(1):155-65.
119. Lefebvre S, Burglen L, Frezal J, Munnich A, Melki J. The role of the SMN gene in proximal spinal muscular atrophy. Human Molecular Genetics 1998;7(10):1531-6.
120. Lewelt A, Newcomb TM, Swoboda KJ. New therapeutic approaches to spinal muscular atrophy. Current Neurology and Neuroscience Reports 2012;12(1):42-53.
121. Liang WC, Yuo CY, Chang JG, Chen YC, Chang YF, Wang HY, et al. The effect of hydroxyurea in spinal muscular atrophy cells and patients. Journal of the Neurological Sciences 2008;268(1-2):87-94.
122. Little D, Valori CF, Mutsaers CA, Bennett EJ, Wyles M, Sharrack B, et al. PTEN depletion decreases disease severity and modestly prolongs survival in a mouse model of spinal muscular atrophy. Molecular Therapy 2015;23(2):270-7.
123. Liu H, Yazdani A, Murray LM, Beauvais A, Kothary R. The sm-independent beneficial effects of trichostatin A on an intermediate mouse model of spinal muscular atrophy. PLoS One 2014;9(7):e101225.
124. Liu M, Hammers DW, Barton ER, Sweeney HL. Activin receptor type IIB inhibition improves muscle phenotype and function in a mouse model of spinal muscular atrophy. PLoS One 2016;11(11):e0166803.
125. Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proceedings of the National Academy of Sciences of the United States of America 1999;96:6307-11.
126. Liu M, Hammers DW, Barton ER, Sweeney HL. Activin receptor type IIB inhibition improves muscle phenotype and function in a mouse model of spinal muscular atrophy. PLoS One 2016;11(11):e0166803.
127. Lunn MR, Root DE, Martino AM, Flaherty SP, Kelley BP, Coovert DD, et al. Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism. Chemistry & Biology 2004;11(11):1489-93.
128. Lunn MR, Wang CH. Spinal muscular atrophy. Lancet 2008;371(9630):2120-33.
129. Mattis VB, Ebert AD, Fosso MY, Chang CW, Lorson CL. Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model. Human Molecular Genetics 2009;18(20):3906-13.
130. Mattis VB, Fosso MY, Chang CW, Lorson CL. Subcutaneous administration of TC007 reduces disease severity in an animal model of SMA. BMC Neuroscience 2009;30(10):142.
131. Mattis VB, Tom Chang CW, Lorson CL. Analysis of a read-through promoting compound in a severe mouse model of spinal muscular atrophy. Neuroscience Letters 2012;525(1):72-5.
132. McWhorter ML, Monani UR, Burghes AH, Beattie CE. Knockdown of the survival motor neuron (smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding. The Journal of Cell Biology 2003;162(5):919-31.
133. Higgins JP, Lasserson T, Chandler J, Tovey D, Churchill R. Methodological Expectations of Cochrane Intervention Reviews. Vol. 1.02, London: Cochrane, 2018.
134. Melki J, Abdelhak S, Sheth P, Bachelot MF, Burlet P, Marcadet A, et al. Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q. Nature 1990;344(6268):767-8.
135. Melki J, Sheth P, Abdelhak S, Burlet P, Bachelot MF, Lathrop MG, et al. Mapping of acute (type I) spinal muscular atrophy to chromosome 5q12-q14. The French Spinal Muscular Atrophy Investigators. Lancet 1990;336(8710):271-3.
136. Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac L, Kissel JT, et al. Gene therapy for spinal muscular atrophy type 1 shows potential to improve survival and motor functional outcomes. Molecular Therapy 2016;24(Suppl 1):S190. [WOS:000375264200475]
137. Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurology 2012;11(5):443-52.
138. Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscular Disorders 2018;28(2):103-15.
139. Merlini L, Solari A, Vita G, Bertini E, Minetti C, Mongini T, et al. Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study. Journal of Child Neurology 2003;18(8):537-41.
140. Meyer K, Ferraiuolo L, Schmelzer L, Braun L, McGovern V, Likhite S, et al. Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose–response study in mice and nonhuman primates. Molecular Therapy 2015;23(3):477-87.
141. Miller RG, Petajan JH, Bryan WW, Armon C, Barohn RJ, Goodpasture JC, et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group. Annals of Neurology 1996;39(2):256-60.
142. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097]
143. Mohseni J, Zabidi-Hussin ZA, Sasongko TH. Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy. Genetics and Molecular Biololgy 2013;36(3):299-307.
144. Mohseni J, Al-Najjar BO, Wahab HA, Zabidi-Hussin ZA, Sasongko TH. Transcript, methylation and molecular docking analyses of the effects of HDAC inhibitors, SAHA and Dacinostat, on SMN2 expression in fibroblasts of SMA patients. Journal of Human Genetics 2016;61:823-30.
145. Munsat TL, Davies KE. International SMA consortium meeting (26-28 June 1992, Bonn, Germany). Neuromuscular Disorders 1992;2(5-6):423-8.
146. Murray LM, Comley LH, Thomson D, Parkinson N, Talbot K, Gillingwater TH. Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Human Molecular Genetics 2008;17(7):949-62. [PUBMED: 18065780]
147. Naryshkin NA, Weetall M, Dakka A, Narasimhan J, Zhao X, Feng Z, et al. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science 2014;345(6197):688-93.
148. NCT02628743. A study to evaluate long term safety, tolerability, and effectiveness of olesoxime in patients with spinal muscular atrophy [Multicenter, open-label, single arm study to evaluate long-term safety, tolerability, and effectiveness of 10 mg/kg olesoxime in patients with SMA]. clinicaltrials.gov/show/NCT02628743 (first received 1 December 2015). [2015-001589-25; BN29854; EUCTR2015-001589-25-GB; NCT02628743]
149. Nicole S, Diaz CC, Frugier T, Melki J. Spinal muscular atrophy: recent advances and future prospects. Muscle & Nerve 2002;26(1):4-13.
150. Ning K, Drepper C, Valori CF, Ahsan M, Wyles M, Higginbottom A, et al. PTEN depletion rescues axonal growth defect and improves survival in SMN-deficient motor neurons. Human Molecular Genetics 2010;19(16):3159-68.
151. Nizzardo M, Simone C, Salani S, Ruepp MD, Rizzo F, Ruggieri M, et al. Effect of combined systemic and local morpholino treatment on the spinal muscular atrophy Δ7 mouse model phenotype. Clinical Therapeutics 2014;36(3):340-56.
152. Nurputra DK, Lai PS, Harahap NI, Morikawa S, Yamamoto T, Nishimura N, et al. Spinal muscular atrophy: from gene discovery to clinical trials. Annals of Human Genetics 2013;77(5):435-63.
153. NCT02386553. A study of multiple doses of ionis smnrx (ISIS 396443) delivered to infants with genetically diagnosed and presymptomatic spinal muscular atrophy (NURTURE) [An open-label study to assess the efficacy, safety, tolerability, and pharmacokinetics of multiple doses of IONIS 396443 delivered intrathecally to subjects with genetically diagnosed and presymptomatic spinal muscular atrophy.]. www.clinicaltrials.gov/show/NCT02386553 (first received 27 February 2015). [2014-002098-12; 232SM201; NCT02386553]
154. Oskoui M, Levy G, Garland CJ, Gray JM, O'Hagen J, De Vivo DC, et al. The changing natural history of spinal muscular atrophy type I. Neurology 2007;69:1931-6.
155. Osman EY, Miller MR, Robbins KL, Lombardi AM, Atkinson AK, Brehm AJ, et al. Morpholino antisense oligonucleotides targeting intronic repressor element 1 improve phenotype in SMA mouse models. Human Molecular Genetics 2015;23(18):4832-45.
156. Osman EY, Washington CW, Kaifer KA, Mazzasette C, Patitucci TN, Florea KM, et al. Optimization of morpholino antisense oligonucleotides targeting the intronic repressor element1 in spinal muscular atrophy. Molecular Therapy 2016;24(9):1592-601.
157. Parker GC, Li X, Anguelov RA, Toth G, Cristescu A, Acsadi G. Survival motor neuron protein regulates apoptosis in an in vitro model of spinal muscular atrophy. Neurotoxicity Research 2008;13(1):39-48.
158. Passini MA, Bu J, Richards AM, Kinnecom C, Sardi SP, Stanek LM, et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Science Translational Medicine 2011;3(72):72ra18.
159. Pellizzoni L, Kataoka N, Charroux B, Dreyfuss G. A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing. Cell 1998;95(5):615-24.
160. Piepers S, van den Berg LH, Brugman F, Scheffer H, Ruiterkamp-Versteeg M, van Engelen BG, et al. A natural history study of late onset spinal muscular atrophy types 3b and 4. Journal of Neurology 2008;255(9):1400-4. [DOI: 10.1007/s00415-008-0929-0]
161. Piepers S, Cobben JM, Sodaar P, Jansen MD, Wadman RI, Meester-Delver A, et al. Quantification of SMN protein in leucocytes from spinal muscular atrophy patients: effects of treatment with valproic acid. Journal of Neurology, Neurosurgery, and Psychiatry 2011;82(8):850-2.
162. Porensky PN, Burghes AH. Antisense oligonucleotides for the treatment of spinal muscular atrophy. Human Gene Therapy 2013;24(5):489-98.
163. NCT03779334. A study of risdiplam in infants with genetically diagnosed and presymptomatic spinal muscular atrophy (Rainbowfish) [An open-label study of risdiplam in infants with genetically diagnosed and presymptomatic spinal muscular atrophy]. www.clinicaltrial.gov (first date recieved 18 December 2018). [BN40703; NCT03779334]
164. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
165. Riessland M, Brichta L, Hahnen E, Wirth B. The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Human Genetics 2006;120(1):101-10.
166. Riessland M, Ackermann B, Förster A, Jakubik M, Hauke J, Garbes L, et al. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Human Molecular Genetics 2010;19(8):1492-1506.
167. Riessland M, Kaczmarek A, Schneider S, Swoboda KJ, Löhr H, Bradler C, et al. Neurocalcin delta suppression protects against spinal muscular atrophy in humans and across species by restoring impaired endocytosis. American Journal of Human Genetics 2017;100(2):297-315.
168. Robbins KL, Glascock JJ, Osman EY, Miller MR, Lorson CL. Defining the therapeutic window in a severe animal model of spinal muscular atrophy. Human Molecular Genetics 2014;23(17):4559-68.
169. Rossoll W, Jablonka S, Andreassi C, Kröning AK, Karle K, Monani UR, et al. Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons. Journal of Cell Biology 2003;163(4):801-12.
170. Russman BS, Iannacone ST, Buncher CR, Samaha FJ, White M, Perkins B, et al. Spinal muscular atrophy: new thoughts on the pathogenesis and classification schema. Journal of Child Neurology 1992;7(4):347-53.
171. Saito T, Nurputra DK, Harahap NI, Harahap IS, Yamamoto H, Muneshige E, et al. A study of valproic acid for patients with spinal muscular atrophy. Neurology and Clinical Neuroscience 2015;3:49-57.
172. Schreml J, Riessland M, Paterno M, Garbes L, Roßbach K, Ackermann B, et al. Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585. European Journal of Human Genetics 2013;21(6):643-52.
173. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
174. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
175. Seo J, Howell MD, Singh NN, Singh RN. Spinal muscular atrophy: an update on therapeutic progress. Biochimica Biophysica Acta 2013;1832(12):2180-90.
176. Shababi M, Lorson CL. Optimization of SMN trans-splicing through the analysis of SMN introns. Journal Molecular Neuroscience 2012;46(3):459-69.
177. Singh J, Salcius M, Liu SW, Staker BL, Mishra R, Thurmond J, et al. DcpS as a therapeutic target for spinal muscular atrophy. ACS Chemical Biology 2008;3(11):711-22.
178. Skordis LA, Dunckley MG, Yue B, Eperon IC, Muntoni F. Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proceedings of National Acadamy of Sciences of the United States of America April 2003;100(7):4114-9.
179. SPACE. SPACE trial SMA and Pyridostigmine in Adults and Children; Experimental trial to assess effect of pyridostigmine compared to placebo in patients with spinal muscular atrophy types 2, 3 and 4 [SPACE trial SMA and Pyridostigmine in Adults and Children; Efficacy trial Phase II, mono-center, doubleblind, placebo-controlled, crossover trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2, 3 and 4 - SPACE trial]. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011-004369-34-NL (first received 3 November 2014). [EUCTR2011-004369-34-NL]
180. Staropoli JF, Li H, Chun SJ, Allaire N, Cullen P, Thai A, et al. Rescue of gene-expression changes in an induced mouse model of spinal muscular atrophy by an antisense oligonucleotide that promotes inclusion of SMN2 exon 7. Genomics 2015;105(4):220-8.
181. Stavarachi M, Apostol P, Toma M, Cimponeriu D, Gavrila L. Spinal muscular atrophy disease: a literature review for therapeutic strategies. Journal of Medicine and Life January-March 2010;3(1):3-9.
182. STOPSMA - NCT00528268. Study to evaluate sodium phenylbutyrate in pre-symptomatic infants with spinal muscular atrophy (STOPSMA) [Prospective phase I/II study to evaluate effects of sodium phenylbutyrate in pre-symptomatic infants with spinal muscular atrophy]. www.clinicaltrials.gov/show/NCT00528268 (first received 10 September 2007). [1R01HD054599-01; 22183; NCT00528268]
183. Sumner CJ, Huynh TN, Markowitz JA, Perhac JS, Hill B, Coovert DD, et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Annals of Neurology 2003;54(5):647-54.
184. Sumner CJ. Molecular mechanisms of spinal muscular atrophy. Journal of Child Neurology 2007;22(8):979-89.
185. Swoboda KJ, Prior TW, Scott CB, McNaught TP, Wride MC, Reyna SP, et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Annals of Neurology 2005;57(5):704-12.
186. Swoboda KJ, Kissel JT, Crawford TO, Bromberg MB, Acsadi G, D'Anjou G, et al. Perspectives on clinical trials in spinal muscular atrophy. Journal of Child Neurology 2007;22(8):957-66.
187. Talbot K. Spinal muscular atrophy. Journal of Inherited Metabolic Diseases 1999;22(4):545-54.
188. Thomas NH, Dubowitz V. The natural history of type I (severe) spinal muscular atrophy. Neuromuscular Disorders 1994;4(5-6):497-502.
189. Thurmond J, Butchbach ME, Palomo M, Pease B, Rao M, Bedell L, et al. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy. Journal of Medicinal Chemistry 2008;51(3):449-69.
190. Ting CH, Lin CW, Wen SL, Hsieh-Li HM, Li H. Stat5 constitutive activation rescues defects in spinal muscular atrophy. Human Molecular Genetics 2007;16(5):499-514.
191. Tisdale S, Pellizzoni L. Disease mechanisms and therapeutic approaches in spinal muscular atrophy. Journal of Neuroscience 2015;35(23):8691-700.
192. Tsai LK, Yang CC, Hwu WL, Li H. Valproic acid treatment in six patients with spinal muscular atrophy. European Journal of Neurology 2007;14(12):e8-9.
193. Tseng YT, Chen CS, Jong YJ, Chang FR, Lo YC. Loganin possesses neuroprotective properties, restores SMN protein and activates protein synthesis positive regulator Akt/mTOR in experimental models of spinal muscular atrophy. Pharmacological Research 2016;111:58-75.
194. Uzunallı G, Bora-Tatar G, Dayangaç-Erden D, Erdem-Yurter H. Effects of flavonoid quercetin on survival of motor neuron gene expression. Cell Biology International 2015;39(3):350-4.
195. Valori CF, Ning K, Wyles M, Mead RJ, Grierson AJ, Shaw PJ, et al. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Science Translational Medicine 2010;35:35-42.
196. Van Meerbeke JP, Gibbs RM, Plasterer HL, Miao W, Feng Z, Lin MY, et al. The DcpS inhibitor RG3039 improves motor function in SMA mice. Human Molecular Genetics 2013;22(20):4074-83.
197. Wadman RI, Stam M, Gijzen M, Lemmink HH, Snoeck IN, Wijngaarde CA, et al. Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0-4. Journal of Neurology, Neurosurgery and Psychiatry 2017;88(4):365-7.
198. Wadman RI, van der Pol WL, Bosboom WMJ, van den Berg LH, Iannaccone ST, Vrancken AFJE. Drug treatment for spinal muscular atrophy types II and III. Cochrane Database of Systematic Reviews (in press). [DOI: 10.1002/14651858.CD006282.pub5]
199. Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, et al. Consensus statement for standard of care in spinal muscular atrophy. Journal of Child Neurology 2007;22(8):1027-49.
200. Weihl CC, Connolly AM, Pestronk A. Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology 2006;67(3):500-1.
201. Wirth B, Brichta L, Hahnen E. Spinal muscular atrophy: from gene to therapy. Seminars in Pediatric Neurology 2006;13(2):121-31.
202. Wishart TM, Mutsaers CA, Riessland M, Reimer MM, Hunter G, Hannam ML, et al. Dysregulation of ubiquitin homeostasis and β-catenin signaling promote spinal muscular atrophy. Journal of Clinical Investigation 2014;124(4):1821-34.
203. Woll MG, Qi H, Turpoff A, Zhang N, Zhang X, Chen G, et al. Discovery and Optimization of Small Molecule Splicing Modifiers of Survival Motor Neuron 2 as a Treatment for Spinal Muscular Atrophy. Journal of Medicinal Chemistry 2016;59(13):6070-85.
204. Wolstencroft EC, Mattis V, Bajer AA, Young PJ, Lorson CL. A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels. Human Molecular Genetics 2005;14(9):1199-1210.
205. Wong BL, Hynan LS, Iannaccone ST, AmSMART Group. A randomized, placebo-controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease 2007;8(3):101-10.
206. Woo CJ, Maier VK, Davey R, Brennan J, Li G, Brothers J, et al. Gene activation of SMN by selective disruption of lncRNA-mediated recruitment of PRC2 for the treatment of spinal muscular atrophy. Proceedings of the National Academy of Sciences of the United States of America 2017;114(8):E1509-E1518.
207. Yuo CY, Lin HH, Chang YS, Yang WK, Chang JG. 5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells. Annals of Neurology 2008;63(1):26-34.
208. Zanetta C, Nizzardo M, Simone C, Monguzzi E, Bresolin N, Comi GP, et al. Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials. Clinical Therapeutics 2014;36(1):128-40.
209. Zerres K, Davies KE. 59th ENMC International Workshop: Spinal Muscular Atrophies: recent progress and revised diagnostic criteria 17-19 April 1998, Soestduinen, The Netherlands. Neuromuscular Disorders 1999;9(4):272-8.
210. Zhang ML, Lorson CL, Androphy EJ, Zhou J. An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA. Gene Therapy 2001;8(20):1532-8.
211. Zhou H, Janghra N, Mitrpant C, Dickinson RL, Anthony K, Price L, et al. A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice. Human Gene Therapy 2013;24(3):331-42.
212. Zhou H, Meng J, Marrosu E, Janghra N, Morgan J, Muntoni F. Repeated low doses of morpholino antisense oligomer: an intermediate mouse model of spinal muscular atrophy to explore the window of therapeutic response. Human Molecular Genetics 2015;24(22):6265-77.
213. Zou T, Ilangovan R, Yu F, Xu Z, Zhou J. SMN protects cells against mutant SOD1 toxicity by increasing chaperone activity. Biochemical and Biophysical Research Communication 2007;364(4):850-5.
214. Bosboom WM, Van den Berg LH, Iannaccone ST, Vrancken AF, Wokke JHJ. Drug treatment for spinal muscular atrophy type I. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD006281]
215. Bosboom WM, Vrancken AF, van den Berg LH, Wokke JH, Iannaccone ST. Drug treatment for spinal muscular atrophy type I. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD006281.pub2]
216. Wadman RI, Bosboom WM, van den Berg LH, Wokke JH, Iannaccone ST, Vrancken AF. Drug treatment for spinal muscular atrophy type I. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD006281.pub3]